Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

N-bridged selective androgen receptor modulators and methods of use thereof

An androgen receptor and selective technology, applied in diseases, pharmaceutical formulations, organic active ingredients, etc., can solve problems such as easy damage, weakened physical condition, and harmful personal health

Inactive Publication Date: 2008-12-31
UNIV OF TENNESSEE RES FOUND
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, changes that occur during sarcoid wasting can result in a weakened physical condition that is detrimental to the individual's health, leading to increased susceptibility to infection, poor performance status, and vulnerability to injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • N-bridged selective androgen receptor modulators and methods of use thereof
  • N-bridged selective androgen receptor modulators and methods of use thereof
  • N-bridged selective androgen receptor modulators and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0258] The preparation of pharmaceutical compositions containing active ingredients is known in the art. Typically, such compositions are formulated as polypeptide aerosols for administration to the nasopharynx, or as injectable solutions or suspensions. However, solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared. The formulation may also be emulsified. The active therapeutic ingredient is usually mixed with excipients which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, etc. or combinations thereof.

[0259] In addition, the composition can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, which enhance the effectiveness of the active ingredients.

[0260] The active ingredients can be formulated into compositions in the form of neutral pharmaceutically acce...

Embodiment 1

[0267] Synthesis of N-bridged selective androgen modulator compounds

[0268] A. Chemistry

[0269] According to route 1 ( figure 1 ) to synthesize the N-bridged selective androgen modulator compound (SARM) of the present invention. First, the synthesis was carried out in two separate steps—isolating the epoxide (S)-5 and then opening the epoxide. These steps were combined into a two-step one-pot process, where after epoxide formation, the solvent was removed and the resulting residue was immediately subjected to an opening step. The first step proceeded cleanly and completely to the epoxide by TLC. The epoxide is opened with the appropriate substituted aniline in hexafluoroisopropanol. Aromatic amines are extremely non-nucleophilic; therefore the epoxide must be formed and opened in the presence of hexafluoroisopropanol, which increases the electrophilicity of the epoxide.

[0270] B. Synthesis

[0271] S-3-(4-acetylamino-phenylamino)-2-hydroxyl-2-methyl-N-(4-nitro-3-tr...

Embodiment 2

[0274] Androgen receptor binding affinity of N-bridged selective androgen modulator compounds

[0275] method

[0276] Using a competitive binding assay as previously described (Kirkovsky, L. et al., Chiralnonsteroidal affinity ligands for tbe androgen receptor. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. J. Med. Chem. 2000, 43, 581-590 ) to determine AR binding affinity. Briefly, AR binding studies were performed as follows: increasing concentrations (10 -3 nM to 10000nM) of each ligand and cytosol, and the saturating concentration 3 H-Mibobolone (MIB) (1 nm) was incubated together at 4°C for 18 hours. The incubation also contained 1000 nM triamcinolone acetonide to block the interaction of MIB with the progesterone receptor. To determine non-specific binding, a separate experiment was performed by adding 1000 nM MIB to the incubation. Separation of bound and free radioactivity was achieved at the end of the incubation by the hydroxyapatit...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

This invention provides a class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (SARM). Several of the SARM compounds have been found to have an unexpected androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. Other SARM compounds have been found to have an unexpected antiandrogenic activity of a nonsteroidal ligand for the androgen receptor. The SARM compounds, either alone or as a composition, are useful for a) male contraception; b) treatment of a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Aging Male (ADAM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss, anemia, obesity, sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, alterations in mood and cognition and prostate cancer; c) treatment of conditions associated with Androgen Decline in Female (ADIF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, alterations in cognition and mood, depression, anemia, hair loss, obesity, endometriosis, breast cancer, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute and / or chronic muscular wasting conditions; e) preventing and / or treating dry eye conditions; f) oral androgen replacement therapy; and / or g) decreasing the incidence of, halting or causing a regression of prostate cancer.

Description

[0001] This application is a divisional application of the Chinese patent application 03819545.3 with the title of "N-bridged selective androgen receptor modulator and its use" submitted on June 17, 2003. technical field [0002] The present invention relates to a new class of androgen receptor targeting agents (ARTAs) which exhibit androgenic and anabolic activity of non-steroidal ligands of the androgen receptor. This agent defines a new subclass of compounds, which are selective androgen receptor modulators (SARMs), for a) male contraception; b) treatment of a variety of hormone-related conditions, such as those associated with decreased androgen in aging men ( ADAM) related disorders; c) treatment of female androgen-decreased (ADIF) related disorders; d) treatment and / or prevention of acute and / or chronic muscle wasting; e) prevention and / or treatment of dry eye; f) oral androgen replacement therapy; and / or g) reducing the incidence of prostate cancer, preventing prostate ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07C237/10C07C255/60C07D211/72C07D233/44C07D239/02A61K31/415A61K31/44A61K31/505A61K31/65A61P5/30A61P43/00A61P3/04A61K31/167A61K31/277A61P5/24A61P5/26A61P5/28A61P7/06A61P13/08A61P15/00A61P15/10A61P15/16A61P17/14A61P19/08A61P19/10A61P21/00A61P25/24A61P25/28A61P27/02A61P35/00C07C237/04
CPCA61K31/415A61K31/44A61K31/505A61K31/65C07C237/10C07C255/60C07D211/72C07D233/44C07D239/02A61P13/08A61P15/00A61P15/10A61P15/16A61P17/14A61P19/08A61P19/10A61P21/00A61P25/24A61P25/28A61P27/02A61P3/04A61P35/00A61P5/24A61P5/26A61P5/28A61P7/06C07C233/07C07C233/15C07C233/12
Inventor 詹姆斯·多尔顿杜安·D.·米勒克雷格·A.·马赫夫卡高文清
Owner UNIV OF TENNESSEE RES FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com